All In Biotech

Drug Trial Radar · NCT06343792

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

Phase 2 Open Label Prospective Dose-Ranging Clinical Trial With Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Aug 31, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
ReAlta Life Sciences, Inc.Industry
Sponsor type
Industry
Collaborators
CTI Clinical Trial and Consulting Services
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-refractory.

Conditions

  • Steroid Refractory GVHD

Interventions

  • RLS-0071Drug

    RLS-0071 will be administered for 7 or 14 days according to the assigned dose group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: Day 1 to Day 180
  2. Overall Response Rate (ORR) of RLS-0071Time frame: Day 1 to Day 28

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • Site 1091

    Duarte, California · Active not recruiting

  • Site 1343

    Los Angeles, California · Active not recruiting

  • Site 1318

    Atlanta, Georgia · Active not recruiting

  • Site 1068

    St Louis, Missouri · Active not recruiting

  • Site 1100

    Cincinnati, Ohio · Active not recruiting

  • Site 1382

    Columbus, Ohio · Active not recruiting

  • Site 3242

    Freiburg im Breisgau, Germany · Recruiting

  • Site 3360

    Madrid, Spain · Recruiting

  • Site 3227

    Salamanca, Spain · Recruiting

  • Site 3101

    Seville, Spain · Recruiting

  • Site 3101

    Seville, SE, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.